WO2009129700A1 - 螺环膦-噁唑啉和制备方法及其应用 - Google Patents
螺环膦-噁唑啉和制备方法及其应用 Download PDFInfo
- Publication number
- WO2009129700A1 WO2009129700A1 PCT/CN2009/070229 CN2009070229W WO2009129700A1 WO 2009129700 A1 WO2009129700 A1 WO 2009129700A1 CN 2009070229 W CN2009070229 W CN 2009070229W WO 2009129700 A1 WO2009129700 A1 WO 2009129700A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituted phenyl
- group
- sec
- tert
- amino
- Prior art date
Links
- 125000003003 spiro group Chemical group 0.000 title claims abstract description 33
- 230000015572 biosynthetic process Effects 0.000 title abstract description 7
- 238000003786 synthesis reaction Methods 0.000 title abstract description 7
- YCOOYCDRESLMFP-UHFFFAOYSA-N [P].O1C=NCC1 Chemical compound [P].O1C=NCC1 YCOOYCDRESLMFP-UHFFFAOYSA-N 0.000 title abstract 3
- -1 α- substituted acrylic acid Chemical class 0.000 claims abstract description 158
- 238000006243 chemical reaction Methods 0.000 claims abstract description 53
- 238000009903 catalytic hydrogenation reaction Methods 0.000 claims abstract description 22
- 239000003446 ligand Substances 0.000 claims abstract description 19
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 58
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 30
- 239000003054 catalyst Substances 0.000 claims description 25
- NHFAABIHBNXKDT-UHFFFAOYSA-N 4,5-dihydro-1,3-oxazole;phosphane Chemical compound P.C1CN=CO1 NHFAABIHBNXKDT-UHFFFAOYSA-N 0.000 claims description 23
- 125000002252 acyl group Chemical group 0.000 claims description 22
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 18
- 125000000217 alkyl group Chemical group 0.000 claims description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 125000004185 ester group Chemical group 0.000 claims description 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- 239000012327 Ruthenium complex Substances 0.000 claims description 12
- 125000004423 acyloxy group Chemical group 0.000 claims description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 125000001188 haloalkyl group Chemical group 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- RRKODOZNUZCUBN-CCAGOZQPSA-N (1z,3z)-cycloocta-1,3-diene Chemical compound C1CC\C=C/C=C\C1 RRKODOZNUZCUBN-CCAGOZQPSA-N 0.000 claims description 8
- BTHBTTSIBCWHHH-UHFFFAOYSA-N 2-[4-(2-methylpropyl)phenyl]prop-2-enoic acid Chemical compound CC(C)CC1=CC=C(C(=C)C(O)=O)C=C1 BTHBTTSIBCWHHH-UHFFFAOYSA-N 0.000 claims description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 8
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 8
- 125000002541 furyl group Chemical group 0.000 claims description 8
- 125000005059 halophenyl group Chemical group 0.000 claims description 8
- 125000001624 naphthyl group Chemical group 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical group 0.000 claims description 7
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 6
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 claims description 6
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 claims description 6
- 239000000758 substrate Substances 0.000 claims description 6
- 125000000335 thiazolyl group Chemical group 0.000 claims description 6
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 claims description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 5
- 239000012359 Methanesulfonyl chloride Substances 0.000 claims description 5
- 239000000654 additive Substances 0.000 claims description 5
- 238000009876 asymmetric hydrogenation reaction Methods 0.000 claims description 5
- 239000000460 chlorine Substances 0.000 claims description 5
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 4
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 claims description 4
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 claims description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims description 4
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 4
- 239000005977 Ethylene Substances 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 4
- 230000000996 additive effect Effects 0.000 claims description 4
- 125000002723 alicyclic group Chemical group 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 4
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 claims description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
- 159000000000 sodium salts Chemical class 0.000 claims description 4
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 claims description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims description 4
- ODWASQWJJUOKNN-UHFFFAOYSA-N 2-phenoxyprop-2-enoic acid Chemical compound OC(=O)C(=C)OC1=CC=CC=C1 ODWASQWJJUOKNN-UHFFFAOYSA-N 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 3
- 229910052782 aluminium Inorganic materials 0.000 claims description 3
- 150000001450 anions Chemical class 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 239000007858 starting material Substances 0.000 claims description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 claims description 2
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 2
- USANCVVZOHSATA-UHFFFAOYSA-N 2-methylidene-4-phenylbutanoic acid Chemical compound OC(=O)C(=C)CCC1=CC=CC=C1 USANCVVZOHSATA-UHFFFAOYSA-N 0.000 claims description 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 238000005349 anion exchange Methods 0.000 claims description 2
- 229910052786 argon Inorganic materials 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 125000004744 butyloxycarbonyl group Chemical group 0.000 claims description 2
- 150000007942 carboxylates Chemical class 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000004410 cyclooctyloxy group Chemical group C1(CCCCCCC1)O* 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 125000000131 cyclopropyloxy group Chemical group C1(CC1)O* 0.000 claims description 2
- 229940043279 diisopropylamine Drugs 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 239000011630 iodine Substances 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 claims description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 2
- 125000005929 isobutyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])OC(*)=O 0.000 claims description 2
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 claims description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000005932 isopentyloxycarbonyl group Chemical group 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical group CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 claims description 2
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 2
- 125000006606 n-butoxy group Chemical group 0.000 claims description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 claims description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000005244 neohexyl group Chemical group [H]C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 125000005933 neopentyloxycarbonyl group Chemical group 0.000 claims description 2
- SJYNFBVQFBRSIB-UHFFFAOYSA-N norbornadiene Chemical group C1=CC2C=CC1C2 SJYNFBVQFBRSIB-UHFFFAOYSA-N 0.000 claims description 2
- 230000003287 optical effect Effects 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 229960003975 potassium Drugs 0.000 claims description 2
- 239000011736 potassium bicarbonate Substances 0.000 claims description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
- 229940093956 potassium carbonate Drugs 0.000 claims description 2
- 235000011181 potassium carbonates Nutrition 0.000 claims description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 2
- 229940086066 potassium hydrogencarbonate Drugs 0.000 claims description 2
- 229940093932 potassium hydroxide Drugs 0.000 claims description 2
- 235000011118 potassium hydroxide Nutrition 0.000 claims description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 2
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000004742 propyloxycarbonyl group Chemical group 0.000 claims description 2
- 125000005920 sec-butoxy group Chemical group 0.000 claims description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 239000012312 sodium hydride Substances 0.000 claims description 2
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 125000000542 sulfonic acid group Chemical group 0.000 claims description 2
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 claims description 2
- 125000005934 tert-pentyloxycarbonyl group Chemical group 0.000 claims description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 5
- 239000004912 1,5-cyclooctadiene Substances 0.000 claims 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims 1
- VYXHVRARDIDEHS-UHFFFAOYSA-N 1,5-cyclooctadiene Chemical compound C1CC=CCCC=C1 VYXHVRARDIDEHS-UHFFFAOYSA-N 0.000 claims 1
- MCIIDRLDHRQKPH-UHFFFAOYSA-N 2-methyl-3-phenylpropanoic acid Chemical compound OC(=O)C(C)CC1=CC=CC=C1 MCIIDRLDHRQKPH-UHFFFAOYSA-N 0.000 claims 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims 1
- 125000005036 alkoxyphenyl group Chemical group 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 229940116229 borneol Drugs 0.000 claims 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims 1
- 238000006482 condensation reaction Methods 0.000 claims 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims 1
- 150000004714 phosphonium salts Chemical class 0.000 claims 1
- 229910052709 silver Inorganic materials 0.000 claims 1
- 239000004332 silver Substances 0.000 claims 1
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 1
- 150000007934 α,β-unsaturated carboxylic acids Chemical class 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 12
- 229910052741 iridium Inorganic materials 0.000 abstract description 4
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 3
- 238000005342 ion exchange Methods 0.000 abstract description 2
- 239000002243 precursor Substances 0.000 abstract description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
- 230000000052 comparative effect Effects 0.000 description 12
- 238000003756 stirring Methods 0.000 description 11
- 239000000047 product Substances 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- RYNDYESLUKWOEE-UHFFFAOYSA-N 2-benzylprop-2-enoic acid Chemical compound OC(=O)C(=C)CC1=CC=CC=C1 RYNDYESLUKWOEE-UHFFFAOYSA-N 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000004808 supercritical fluid chromatography Methods 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000002274 desiccant Substances 0.000 description 4
- 238000005984 hydrogenation reaction Methods 0.000 description 4
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000000967 suction filtration Methods 0.000 description 4
- 125000003504 2-oxazolinyl group Chemical group O1C(=NCC1)* 0.000 description 3
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 3
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000002390 rotary evaporation Methods 0.000 description 3
- 229910052707 ruthenium Inorganic materials 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- HPSGLFKWHYAKSF-UHFFFAOYSA-N 2-phenylethyl prop-2-enoate Chemical compound C=CC(=O)OCCC1=CC=CC=C1 HPSGLFKWHYAKSF-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000011914 asymmetric synthesis Methods 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 238000007036 catalytic synthesis reaction Methods 0.000 description 2
- 238000005356 chiral GC Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000004807 desolvation Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000010025 steaming Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- QGHDLJAZIIFENW-UHFFFAOYSA-N 4-[1,1,1,3,3,3-hexafluoro-2-(4-hydroxy-3-prop-2-enylphenyl)propan-2-yl]-2-prop-2-enylphenol Chemical group C1=C(CC=C)C(O)=CC=C1C(C(F)(F)F)(C(F)(F)F)C1=CC=C(O)C(CC=C)=C1 QGHDLJAZIIFENW-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- ZIPLHLLDHUOMHV-UHFFFAOYSA-N O1C=NC=C1.P Chemical compound O1C=NC=C1.P ZIPLHLLDHUOMHV-UHFFFAOYSA-N 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 1
- 241000255969 Pieris brassicae Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012320 chlorinating reagent Substances 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- XPYGGHVSFMUHLH-UUSULHAXSA-N falecalcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(O)(C(F)(F)F)C(F)(F)F)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C XPYGGHVSFMUHLH-UUSULHAXSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000002815 homogeneous catalyst Substances 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- QARBMVPHQWIHKH-KHWXYDKHSA-N methanesulfonyl chloride Chemical group C[35S](Cl)(=O)=O QARBMVPHQWIHKH-KHWXYDKHSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- QBERHIJABFXGRZ-UHFFFAOYSA-M rhodium;triphenylphosphane;chloride Chemical compound [Cl-].[Rh].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QBERHIJABFXGRZ-UHFFFAOYSA-M 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 159000000008 strontium salts Chemical class 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
- 238000007039 two-step reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000011995 wilkinson's catalyst Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
- C07F9/653—Five-membered rings
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/18—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony as complexing atoms, e.g. in pyridine ligands, or in resonance therewith, e.g. in isocyanide ligands C=N-R or as complexed central atoms
- B01J31/189—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony as complexing atoms, e.g. in pyridine ligands, or in resonance therewith, e.g. in isocyanide ligands C=N-R or as complexed central atoms containing both nitrogen and phosphorus as complexing atoms, including e.g. phosphino moieties, in one at least bidentate or bridging ligand
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
- C07C51/36—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by hydrogenation of carbon-to-carbon unsaturated bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0033—Iridium compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0046—Ruthenium compounds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2231/00—Catalytic reactions performed with catalysts classified in B01J31/00
- B01J2231/60—Reduction reactions, e.g. hydrogenation
- B01J2231/64—Reductions in general of organic substrates, e.g. hydride reductions or hydrogenations
- B01J2231/641—Hydrogenation of organic substrates, i.e. H2 or H-transfer hydrogenations, e.g. Fischer-Tropsch processes
- B01J2231/645—Hydrogenation of organic substrates, i.e. H2 or H-transfer hydrogenations, e.g. Fischer-Tropsch processes of C=C or C-C triple bonds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/80—Complexes comprising metals of Group VIII as the central metal
- B01J2531/82—Metals of the platinum group
- B01J2531/827—Iridium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Definitions
- the invention relates to a novel spiro phosphine-oxazoline and a preparation method thereof and application thereof.
- the novel spiro phosphine-oxazole of the present invention is synthesized by a two-step reaction using a substituted 7-diarylphosphino-7-carboxy-1,1'-spirobihydroindole as a starting material. Porphyrin.
- the novel spiro phosphine-oxazoline and the ruthenium precursor are complexed, and then ion exchange is carried out to obtain a ruthenium/spirocyclophosphine-stoichilan complex containing different anions.
- the novel spiro phosphine-oxazoline ruthenium complex is capable of catalyzing the asymmetric hydrogenation of ⁇ -substituted acrylic acid and exhibits high activity and enantioselectivity. Background technique
- Asymmetric catalytic synthesis is currently a hot spot in the field of organic synthetic chemistry research (Ohkuma, T.; Kitamura, M.; Noyori, . Catalytic Asymmetric Synthesis, Wiley, New York, 2000).
- the key to asymmetric catalytic synthesis is the design and synthesis of chiral catalysts with high enantioselectivity and catalytic activity.
- the design and synthesis of chiral catalysts is, in a sense, the design and synthesis of chiral ligands, since chiral ligands are the source of asymmetric induction and control by chiral catalysts.
- Chinese patent CN1884290A discloses a chiral spiro phosphine-oxazoline ligand SIPHOX having a spirocyclic structure skeleton, and the complex catalyst formed by the ligand and ruthenium has a high stereoscopic effect on the asymmetric catalytic hydrogenation reaction of imine. Selectivity, ee value up to 97%, and high reactivity.
- a novel spiro phosphine-oxazoline having no substituent at the 4-position of the oxazoline ring was synthesized using inexpensive and readily available aminoethanol as a starting material.
- the novel spiro phosphine-oxazoline ruthenium complex can catalyze the asymmetric hydrogenation of ⁇ -substituted acrylic acid, exhibits high activity and enantioselectivity, and has high research value and industrialization prospect.
- the present invention discloses a spirocyclic phosphine-oxazoline (I) having the following structural formula:
- R 3 and RRR 6 are respectively H, d ⁇ C 8 ; 3 ⁇ 4 group, haloalkyl group, d ⁇ C 8 alkoxy group, C 2 -C 8 acyloxy group, Ci ⁇ C 8 acyl group, C 2 ⁇ C 8 ester group , (d ⁇ C 8 acyl)amino, bis(d ⁇ C 8 ;3 ⁇ 4yl)amino, halogen, phenyl, d ⁇ C 8 ; 3 ⁇ 4 substituted phenyl, hydroxy substituted phenyl, d ⁇ C 8 alkane Oxy-substituted phenyl, C 2 -C 8 acyl substituted phenyl, halophenyl, amino substituted phenyl, (d ⁇ C 8 acyl)amino substituted phenyl, di (d ⁇ C 8 alkyl) ) amino-substituted phenyl group, d ⁇ C 8 acyl-substituted phenyl,
- R 7 is C VIII [ 8 alkyl, phenyl, d ⁇ C 8 ; 3 ⁇ 4 group substituted phenyl, hydroxy substituted phenyl, sulfonic acid substituted phenyl, Ci ⁇ C 8 alkoxy substituted phenyl , C 2 -C 8 acyloxy substituted phenyl, halophenyl, amino substituted phenyl, (Ci ⁇ C 8 acyl) -amino substituted phenyl, di(d ⁇ C 8 alkyl)amino substituted phenyl, d ⁇ C 8 acyl-substituted phenyl, C 2 ⁇ C 8 ester groups substituted phenyl, naphthyl, furanyl, thiazolyl group Yu;
- the d ⁇ C 8 alkyl group is methyl, ethyl, n-propyl, isopropyl, cyclopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, cyclobutyl, n-pentyl Base, isoamyl, neopentyl, sec-pentyl, tert-amyl, cyclopentyl, n-hexyl, isohexyl, Neohexyl, sec-hexyl, tert-hexyl, cyclohexyl, n-heptyl, isoheptyl, neoheptyl, sec-heptyl, tert-heptyl, cycloheptyl, n-octyl, isooctyl, neooctyl, zhongxin Base, tert-octy
- the d ⁇ C 8 alkoxy group is a methoxy group, an ethoxy group, a n-propoxy group, an isopropoxy group, a cyclopropoxy group, a n-butoxy group, an isobutoxy group, a sec-butoxy group, and a tertiary Butoxy, cyclobutoxy, n-pentyloxy, isopentyloxy, neopentyloxy, sec-pentyloxy, tert-pentyloxy, cyclopentyloxy, n-hexyloxy, isohexyloxy, neohexyloxy , sec-hexyloxy, tert-hexyloxy, cyclohexyloxy, n-heptyloxy, isoheptyloxy, neoheptyloxy, sec-heptyloxy, tert-heptyloxy, cycloheptyloxy, n-
- the d ⁇ C 8 acyl group is formyl, acetyl, propionyl, n-butyryl, isobutyryl, n-pentanoyl, isovaleryl, pivaloyl, pivaloyl, n-hexanoyl, isohexanoyl, neohexyl Acyl, sec-hexanoyl, n-heptanoyl, isoheptanoyl, neoheptanoyl, heptyl, n-octanoyl, isooctanoyl, neooctanoyl, sec-octanoyl, 1-cyclopropylformyl, 1-cyclobutyl Acyl, 1-cyclopentylformyl, 1-cyclohexylformyl, 1-cycloheptylcarbonyl;
- the C 2 -C 8 acyloxy group is acetoxy, propionyloxy, n-butyryloxy, isobutyryloxy, n-pentanoyloxy, isovaleryloxy, sec-pentanoyloxy, Pivaloyloxy, n-hexanoyloxy, isohexanoyloxy, neohexanoyloxy, sec-hexanoyloxy, n-heptanoyloxy, isoheptanoyloxy, neoheptanoyloxy, sec-heptanoyloxy , n-octanoyloxy, isooctanoyloxy, neooctanoyloxy, sec-octanoyloxy, 1-cyclopropylcarbonyloxy, 1-cyclobutylcarbonyloxy, 1-cyclopentyl Acyloxy, 1-cyclohexylcarbonyloxy, 1-cycl
- the C 2 -C 8 ester group is methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, n-pentyloxycarbonyl, isopentyloxycarbonyl, neopentyloxy Carbonyl, sec-pentyloxycarbonyl, tert-pentyloxycarbonyl, cyclopentyloxycarbonyl, n-hexyloxycarbonyl, isohexyloxycarbonyl, neohexyloxycarbonyl, sec-hexyloxycarbonyl, tert-hexyloxycarbonyl, cyclohexyloxycarbonyl, n-heptyloxycarbonyl, Isoheptyloxycarbonyl, neoheptyloxycarbonyl, sec-heptyloxycarbonyl, tert-heptyloxycarbony
- the haloalkyl group is a haloalkyl group of fluorine, chlorine, bromine or iodine.
- the spiro phosphine-oxazoline comprises a racemate, a right-handed body and a left-handed body having the same chemical structural formula but having different stereo structures and optical rotation properties.
- the preparation method of the spiro phosphine-oxazoline of the invention comprises the following steps:
- the obtained amide alcohol compound is catalyzed by 5 to 10 mol% of N,N-dimethyl-4-aminopyridine (DMAP), and is bound by triethylamine or diisopropylethylamine (2 ⁇ 4 mol).
- C specific reaction:
- R 2 , R 3 , RRRR 7 are as defined for compound (I);
- DCC is N,N-dicyclohexylcarbimide;
- HOBt is 1-hydroxybenzotriazole;
- MsCl It is methanesulfonyl chloride.
- the ruthenium complex (II) of spiro phosphine-oxazoline prepared by the spiro phosphine-oxazoline provided by the invention has the following structural formula:
- Is cyclooctadiene; n 0 ⁇ 3; 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 are as defined by the compound (I);
- X is halogen, d ⁇ C 8 Carboxylate, sulfate, tetrakis(3,5-bistrifluoromethylphenyl)borate, tetrakis(pentafluorophenyl)borate, tetrakis(perfluoro-tert-butoxy)aluminum, tetrakis(hexafluoro) Isopropoxy)aluminum ion, hexafluorophosphate, hexafluoroantimonate, tetrafluoroborate or triflate;
- the cyclooctadiene ligand can be substituted by ethylene and norbornadiene;
- the sodium salt can be correspondingly Substituted by potassium, am
- [Ir] is a ruthenium complex of spiro phosphine-oxazoline according to formula ( ⁇ );
- R 8 is halogen, d-C 8 alkyl, haloalkyl, d-C 8 alkane
- the specific process is: under the protection of argon or nitrogen, the catalyst and the substrate are added into the inner tube of the reaction vessel, the additive and the solvent are added, the reaction kettle is sealed and replaced with hydrogen for 3 to 5 times, hydrogen is charged, and the reaction is stirred until the end;
- the catalytic hydrogenation reaction conditions are: the solvent used is [a wide range of alcohols; the amount of the catalyst is 0.001 to 1 mol%; the substrate concentration is 0.001 to 10.0 M; the additives are isopropylamine, tert-butylamine, dimethylamine, diethyl Amine, diisopropylamine, diisopropylethylamine, trimethylamine, triethylamine, 1,8-diazabicyclo[5,4,0]undec-7-ene, 1,4-diaza Bicyclo[2,2,2]octane, sodium hydride, sodium hydroxide, sodium carbonate, sodium hydrogencarbonate, sodium t-butoxide, potassium hydroxide, potassium carbonate, potassium hydrogencarbonate, potassium t-butoxide, barium hydroxide One or several kinds of cesium carbonate; the reaction temperature is 0 ⁇ 100 °C; the hydrogen pressure is 0.1 ⁇ 10 Mpa; the reaction is 0.5 ⁇ 48 hours.
- the invention provides a spirocyclic phosphine-oxazoline and a preparation method thereof and an application thereof, which can overcome the disadvantages of the prior art, and synthesize an oxazoline ring having no substituent at the 4-position using a cheap and easily available aminoethanol as a raw material.
- Novel spiro phosphine-oxazoline The novel spiro phosphine-oxazoline ruthenium complex can catalyze the asymmetric hydrogenation of ⁇ -substituted acrylic acid, exhibits high activity and enantioselectivity, and has high research value and industrialization prospect.
- Me is methyl, u is tert-butyl, Ph is phenyl, Bn is benzyl, An is p-methoxyphenyl, Xyl is 3,5-dimethylphenyl, DMM is 3,5-di Methyl-4-methoxyphenyl, DTB is 3,5-di-tert-butylphenyl, BARF is tetrakis(3,5-bis-trifluoromethylphenyl)borate; NMR is nuclear magnetic resonance, chiral SFC is a supercritical fluid chromatography with a chiral column, and chiral GC is a gas chromatograph with a chiral capillary column; the ee value is the enantiomeric excess.
- Example 1 Preparation of (-N-hydroxyethyl-7'-bis(3,5-di-tert-butylphenyl)phosphino-indole, indole-spiroindan-7-carboxamide
- Re-distilled tetrahydrofuran (THF, 80 mL) was added under ice-cooling, and the reaction was stirred up to room temperature, and a large white precipitate was formed. The reaction was followed by thin layer chromatography until the conversion was complete.
- the ligand (&)-7-(4,5-dihydrooxazol-2-yl)-indole-bis(3,5-di-tert-butylphenyl)phosphino-indole was weighed in a glove box.
- Spiroindoline 3 60 mg, 0.085 mmol
- [Ir(COD)Cl] 2 32 mg, 0.047 mmol
- NaBARF 100 mg, 0.107 mmol
- Comparative Example 1 BARF - Asymmetric catalytic hydrogenation of 2-(4-isobutylphenyl)acrylic acid 5 under the same conditions as in Example 4 using a chiral catalyst L - " 1 1 ", the reaction was as follows: 15%, the ee value of the obtained product was 12%. Comparative Example 2:
- the catalyst [(5* a -DTB-SIPHOX)Ir(COD)]BARF4 (2.4 mg, 0.00125 mmol), 2-benzylacrylic acid 7 (81 mg, 0.5 mmol) and cesium carbonate (82 mg) were weighed in a glove box. , 0.25 mmol) in a reaction inner tube equipped with a stir bar, sealed for use. After taking out, anhydrous methanol (2 mL) was added by a syringe, and the inner tube was placed in a hydrogenation reactor, and the reaction was stirred at room temperature for 12 hours under a hydrogen pressure of 0.6 Mpa. Then, the stirring was stopped, the hydrogen gas was released, and the reaction system was concentrated by steaming.
- the pH was adjusted to 3 with a 3N aqueous hydrochloric acid solution, extracted with diethyl ether (10 mL ⁇ 3), and the organic phase was combined and washed with saturated brine. dry.
- the desiccant is removed by suction filtration, and the product is desalted by rotary distillation to obtain the target product 8 as a colorless oily liquid.
- the conversion was 100% by a 1H NMR analysis, and the yield was 94%.
- Example 6 Asymmetric catalytic hydrogenation of 2-phenethyl acrylate
- the catalyst [(5* a -DTB-SIPHOX)Ir(COD)]BARF4 (2.4 mg, 0.00125 mmol), 2-phenylethyl acrylate 9 (88 mg, 0.5 mmol) and cesium carbonate (82) were weighed in a glove box. Mg, 0.25 mmol) was sealed in a reaction tube equipped with a stir bar. After taking out, anhydrous methanol (2 mL) was added by a syringe, and the inner tube was placed in a hydrogenation reactor, and the reaction was stirred at room temperature for 24 hours under a hydrogen pressure of 0.6 Mpa. Then, the stirring was stopped, the hydrogen gas was released, and the reaction system was concentrated by steaming.
- the pH was adjusted to 3 with a 3N aqueous hydrochloric acid solution, extracted with diethyl ether (10 mL ⁇ 3), and the organic phase was combined and washed with saturated brine. dry.
- the desiccant was removed by suction filtration, and the mixture was evaporated to give the desired product 10 as a colorless oily liquid.
- the yield was 100%, and the yield was 94%.
- the catalyst [(5* a -DTB-SIPHOX)Ir(COD)]BARF4 (4.8 mg, 0.0025 mmol), 2-phenoxyacrylic acid 11 (32 mg, 0.20 mmol) and cesium carbonate (41) were weighed in a glove box. Mg, 0.125 mmol) was sealed in a reaction tube equipped with a stir bar. After taking out, anhydrous methanol (2 mL) was added by a syringe, and the inner tube was placed in a hydrogenation reactor, and the reaction was stirred at 30 ° C for 24 hours under a hydrogen pressure of 0.6 Mpa.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Materials Engineering (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Catalysts (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Description
螺环膦 -噁唑啉和制备方法及其应用 技术领域
本发明涉及一种新型螺环膦 -噁唑啉和制备方法及其应用。具体的讲是以取代的 7-二芳 基膦基—7—羧基 -1 , 1 '—螺二氢茚为起始原料, 经两步反应合成本发明所说的新型螺环膦 -噁唑 啉。 将该新型螺环膦-噁唑啉和铱前体进行络合, 再经过离子交换, 可以得到含不同阴离子 的铱 /螺环膦 -噁峻啉络合物。 该新型螺环膦 -噁唑啉的铱络合物能够催化 α-取代丙烯酸的不 对称氢化反应 , 表现出很高的活性和对映选择性。 背景技术
不对称催化合成是当前有机合成化学研究领域中的热点 (Ohkuma, T.; Kitamura, M.; Noyori, . Catalytic Asymmetric Synthesis, Wiley, New York, 2000 )。不对称催化合成的关键是设 计和合成具有高对映选择性和催化活性的手性催化剂。 手性催化剂的设计和合成, 在某种意 义上就是手性配体的设计和合成,因为手性配体是手性催化剂产生不对称诱导和控制的源泉。 1966年, Wilkinson发现 [R (Ph3P)3Cl]络合物这一高活性均相催化剂, 为不对称催化氢化的发 展提供了前提 ( Osbom, J. A.; Jardine, F. H.; Young, J. R; Wilkinson, G. J. Chem. Soc. A 1966, 1711 )。 1968年, Knowles和 Horner分别报道了首例金属催化的不对称催化反应( Knowles, W. S.; Sabacky, M. J. J. Chem. Soc, Chem. Commun. 1968, 1445; Horner, L.; Siegel, H.; Buthe, H. Angew. Chem. Int. Ed. 1968, 7, 942 )„他们在 Wilkinson催化剂中引入手性单膦配体进行均相不 对称催化氢化, 获得了 15% ee。 这一工作开启了均相不对称催化氢化反应的大门, 同时也促 进了手性配体的发展。 时至今日, 人们发展出的手性配体已多达千余种 ( Cow ^/?m« e Asymmetric Catalysis; Jacobsen, E. N.; Pfaltz, A.; Yamamoto, H., Eds.; Springer- Verlag: Heidelberg. 1999 )。
中国专利 CN1884290A, 公开了具有螺环结构骨架的手性螺环膦 -噁唑啉配体 SIPHOX, 该配体与铱形成的络合物催化剂对亚胺的不对称催化氢化反应具有很高的立体选择性, ee值 最高可达 97%, 同时兼具高反应活性等优点。 但是, 由于在配体合成中使用了光学纯的氨基 醇类化合物作为合成原料, 使 SIPHOX配体的合成成本较高; 同时由于噁唑啉环 4-位上取代 基的位阻效应, 使得某些底物无法靠近金属原子进行配位, 减小了 SIPHOX配体的底物适用 范围。 发明内容
本发明的目的是提供一种螺环膦 -噁唑啉和制备方法及其应用, 可以克服已有技术的缺 点。 使用廉价易得的氨基乙醇作为原料合成了噁唑啉环 4-位上没有取代基的新型螺环膦 -噁 唑啉。 该新型螺环膦 -噁唑啉的铱络合物能够催化 α-取代丙烯酸的不对称氢化反应, 表现出 很高的活性和对映选择性, 具有很高的研究价值和工业化前景。
本发明公开了螺环膦 -噁唑啉( I ), 具有如下的结构式:
其中: n = 0~3; R2分别为 H、 d~C8 ;¾基、 卤代烷基、 d~C8烷氧基、 C2~C8酰! U &、 C广 C8酰基、 C2~C8酯基、 (d~C8酰基)氨基、 二 (C广 C8烷基)氨基、 卤素、 苯基、 C广 烷基 取代的苯基、 羟基取代的苯基、 C广 C8烷氧基取代的苯基、 C2~C8酰氧基取代的苯基、 卤代苯 基、 氨基取代的苯基、 (C广 C8酰基)氨基取代的苯基、 二 (C广〔8烷基)氨基取代的苯基、 Ci~C8 酰基取代的苯基、 C2~C8酯基取代的苯基、 萘基、 呋喃基、 噻喻基, 或并脂环或芳环 (当 n≥ 2时); R1和 R2可以相同, 也可以不同;
R3、 R R R6分别为 H、 d~C8 ;¾基、 卤代烷基、 d~C8烷氧基、 C2~C8酰氧基、 Ci~C8 酰基、 C2~C8酯基、 (d~C8酰基)氨基、 二 (d~C8 ;¾基)氨基、 卤素、 苯基、 d~C8 ;¾基取代的 苯基、 羟基取代的苯基、 d~C8烷氧基取代的苯基、 C2~C8酰 取代的苯基、 卤代苯基、 氨 基取代的苯基、 (d~C8酰基)氨基取代的苯基、 二 (d~C8烷基)氨基取代的苯基、 d~C8酰基取 代的苯基、 C2~C8酯基取代的苯基、 萘基、 呋喃基、 噻喻基, 或 R3~R4、 R5~R6为并脂环或芳 环; R3、 R R5、 R6可以相同, 也可以不同;
R7为 C广〔8烷基、 苯基、 d~C8 ;¾基取代的苯基、 羟基取代的苯基、 磺酸基取代的苯基、 Ci~C8烷氧基取代的苯基、 C2~C8酰氧基取代的苯基、 卤代苯基、 氨基取代的苯基、 (Ci~C8 酰基) -氨基取代的苯基、 二 (d~C8烷基)氨基取代的苯基、 d~C8酰基取代的苯基、 C2~C8酯基 取代的苯基、 萘基、 呋喃基、 噻喻基;
所述的螺环膦 -噁唑啉中:
所述的 d~C8烷基为甲基、 乙基、 正丙基、 异丙基、 环丙基、 正丁基、 异丁基、 仲丁基、 叔丁基、 环丁基、 正戊基、 异戊基、 新戊基、 仲戊基、 叔戊基、 环戊基、 正己基、 异己基、
新己基、 仲己基、 叔己基、 环己基、 正庚基、 异庚基、 新庚基、 仲庚基、 叔庚基、 环庚基、 正辛基、 异辛基、 新辛基、 仲辛基、 叔辛基或环辛基;
所述的 d~C8烷氧基为甲氧基、 乙氧基、 正丙氧基、 异丙氧基、 环丙氧基、 正丁氧基、 异丁氧基、 仲丁氧基、 叔丁氧基、 环丁氧基、 正戊氧基、 异戊氧基、 新戊氧基、 仲戊氧基、 叔戊氧基、 环戊氧基、 正己氧基、 异己氧基、 新己氧基、 仲己氧基、 叔己氧基、 环己氧基、 正庚氧基、 异庚氧基、 新庚氧基、 仲庚氧基、 叔庚氧基、 环庚氧基、 正辛氧基、 异辛氧基、 新辛氧基、 仲辛氧基、 叔辛氧基或环辛氧基;
所述的 d~C8酰基为甲酰基、 乙酰基、 丙酰基、 正丁酰基、 异丁酰基、 正戊酰基、 异戊 酰基、 仲戊酰基、 新戊酰基、 正己酰基、 异己酰基、 新己酰基、 仲己酰基、 正庚酰基、 异庚 酰基、 新庚酰基、 仲庚酰基、 正辛酰基、 异辛酰基、 新辛酰基、 仲辛酰基、 1-环丙基甲酰基、 1-环丁基甲酰基、 1-环戊基甲酰基、 1-环己基甲酰基、 1-环庚基甲酰基;
所述的 C2~C8酰氧基为乙酰氧基、 丙酰氧、 正丁酰氧基、 异丁酰氧基、 正戊酰氧基、 异 戊酰氧基、 仲戊酰氧基、 新戊酰氧基、 正己酰氧基、 异己酰氧基、 新己酰氧基、 仲己酰氧基、 正庚酰氧基、 异庚酰氧基、 新庚酰氧基、 仲庚酰氧基、 正辛酰氧基、 异辛酰氧基、 新辛酰氧 基、 仲辛酰氧基、 1-环丙基甲酰氧基、 1-环丁基甲酰氧基、 1-环戊基甲酰氧基、 1-环己基甲酰 氧基、 1-环庚基甲酰氧基;
所述的 C2~C8酯基为甲氧羰基、 乙氧羰基、 丙氧羰基、 异丙氧羰基、 丁氧羰基、 异丁氧 羰基、 正戊氧羰基、 异戊氧羰基、 新戊氧羰基、 仲戊氧羰基、 叔戊氧羰基、 环戊氧羰基、 正 己氧羰基、 异己氧羰基、 新己氧羰基、 仲己氧羰基、 叔己氧羰基、 环己氧羰基、 正庚氧羰基、 异庚氧羰基、 新庚氧羰基、 仲庚氧羰基、 叔庚氧羰基、 环庚氧羰基;
所述的卤代烷基为含氟、 氯、 溴或碘的卤代烷基。
所述的螺环膦 -噁唑啉包含具有相同的化学结构通式但具有不同的立体结构和旋光性能 的外消旋体、 右旋体和左旋体。
本发明所述的螺环膦 -噁唑啉的制备方法包括如下步骤:
以取代的 7-二芳基膦基 -7'-羧基 -1,1'-螺二氢茚为起始原料, 0~60。C温度下, 在有机溶剂 (四氢呋喃、 二氧六环、 叔丁基甲基醚、 乙二醇二甲醚中的一种或几种) 中, 在 1-羟基苯并 三唑( HOBt, 2-4 mol )和 N,N-二环己基碳酰亚胺( DCC, 3-6 mol M乍用下与氨基乙醇( 2-4 mol ) 缩合反应 10~32小时, 得到相应的酰胺醇化合物;
所得酰胺醇化合物在 5~10 mol%的 N,N-二甲基 -4-氨基吡啶( DMAP ) 的催化下, 以三乙 胺或二异丙基乙基胺(2~4 mol )作为縛酸剂, 和甲磺酰氯, 对甲苯磺酰氯等氯化试剂 (1~1.2
mol )作用, 反应 1~12小时, 得到新型螺环膦-噁唑啉, 所用溶剂为二氯甲烷、 三氯甲烷或 1,2-二氯乙烷中的一种或几种, 反应温度为 0~25。C, 具体反应:
本发明提供的一种由螺环膦 -噁唑啉制备的螺环膦 -噁唑啉的铱络合物 ( II ), 具有如下 的结构式:
其中:
是环辛二烯; n = 0~3; 1 , R2、 R3、 R4、 R5、 R6、 R7的取值如化合物(I ) 所定义; X为卤素、 d~C8的羧酸根、 硫酸根、 四 (3,5-双三氟甲基苯基)硼酸根、 四 (五氟 苯基)硼酸根、 四 (全氟叔丁氧基)铝离子、 四 (六氟异丙氧基)铝离子、 六氟磷酸根、 六 氟锑酸根、 四氟硼酸根或三氟甲磺酸根; 环辛二烯配体可以被乙烯、 降冰片二烯取代; 钠盐 可以被相应的钾盐、 铵盐、 4艮盐或铊盐取代。
所述的螺环膦 -噁唑啉的铱络合物的制备方法是经过如下步骤制备: 在有机溶剂 (二氯 甲烷、三氯甲烷或 1,2-二氯乙烷中的一种或几种)中, 20~50 °C下,螺环膦 -噁唑啉( 1 mol ), 一价铱化合物,如 [Ir(COD)Cl]2 ( COD = 环辛二烯)( 0.5~1 mol ),和钠盐( 1~3 mol )反应 3~24 小时, 制备得到产物,再通过阴离子交换得到具有不同阴离子的螺环膦 -噁唑啉的铱络合物:
其中: n = 0-3; R2、 R3、 R R R6、 R X的取值如化合物 (I )所定义; COD 为环辛二烯; 环辛二烯配体可以被乙烯、 冰片二烯取代。
所述的螺环膦 -噁唑啉的铱络合物的应用是用于催化 α-取代丙烯酸的不对称氢化反应。
其中: [Ir]为式(Π )所述的螺环膦-噁唑啉的铱络合物; R8是卤素、 d~C8烷基、 卤代 烷基、 d~C8烷 |U &、 苯甲氧基、 苯氧基、 C2~C8酰氧基、 d~C8酰基、 C2~C8酯基、 (Ci~C8 酰基)氨基、 二 ( ~〔8烷基)氨基、 苄基、 苯乙基、 苯基、 d~C8 ;¾基取代的苯基、 羟基取代的 苯基、 d~C8烷氧基取代的苯基、 C2~C8酰氧基取代的苯基、卤代苯基、氨基取代的苯基、 (Ci~C8 酰基)氨基取代的苯基、 二 (d~C8烷基)氨基取代的苯基、 d~C8酰基取代的苯基、 C2~C8酯基 取代的苯基、 萘基、 呋喃基、 噻喻基; 星号标记的位置为手性中心。
具体过程是: 在氩气或氮气保护下, 将催化剂和底物加入反应釜内管中, 加入添加剂和 溶剂, 密封反应釜并用氢气置换 3 ~ 5次, 充氢气, 搅拌反应至结束;
所述的催化氢化反应条件是: 所用溶剂是〔广^的醇类; 催化剂用量为 0.001~l mol%; 底物浓度为 0.001~10.0 M; 添加剂为异丙胺、 叔丁胺、 二甲胺、 二乙胺、 二异丙胺、 二异丙 基乙基胺、 三甲胺、 三乙胺、 1,8-二氮杂双环 [5,4,0]十一 -7-烯、 1,4-二氮杂二环 [2,2,2]辛烷、 氢化钠、 氢氧化钠、 碳酸钠、 碳酸氢钠、 叔丁醇钠、 氢氧化钾、 碳酸钾、 碳酸氢钾、 叔丁醇 钾、 氢氧化铯、 碳酸铯中的一种或几种; 反应温度为 0~100 °C; 氢气压力为 0.1~10 Mpa; 反 应 0.5~48小时。
本发明提供了一种螺环膦 -噁唑啉和制备方法及其应用, 可以克服已有技术的缺点, 使 用廉价易得的氨基乙醇作为原料合成了噁唑啉环 4-位上没有取代基的新型螺环膦-噁唑啉。该 新型螺环膦 -噁唑啉的铱络合物能够催化 α-取代丙烯酸的不对称氢化反应 , 表现出很高的活 性和对映选择性, 具有很高的研究价值和工业化前景。
具体实施方式
通过下述实施实例将有助于近一步理解本发明, 但并不限制本发明内容。 本发明的制备 方法可进一步用代表化合物的制备过程体现如下: 一般说明:
实施实例中使用了如下缩写, 其含义如下:
Me是甲基, u是叔丁基, Ph是苯基, Bn是苯甲基, An是对甲氧基苯基, Xyl是 3,5- 二甲基苯基, DMM是 3,5-二甲基 -4-甲氧基苯基, DTB是 3,5-二叔丁基苯基, BARF是四( 3,5- 双三氟甲基苯基)硼酸根; NMR是核磁共振, 手性 SFC是装有手性色谱柱的超临界流体色 谱, 手性 GC是装有手性毛细管柱的气相色谱; ee值为对映异构体过量值。
所用溶剂在使用前用标准操作提纯, 干燥; 所用试剂均为市售或按照已有文献方法合成 得到, 并在使用前提纯。 实施例 1 : ( -N-羟乙基 -7'-二(3,5-二叔丁基苯基)膦基 -Ι,Γ-螺二氢茚 -7-甲酰胺的制备
在 250 mL装有反口塞、 抽气头和磁搅拌的两颈瓶中, 称取 ¾-7-二( 3,5-二叔丁基苯基 ) 膦基 -7'-羧基 -1,1'-螺二氢茚 1 ( 1.0 g, 1.48 mmol )、 氨基乙醇(284 mg, 4.65 mmol )、 1-羟基苯 并三唑( HOBt, 504 mg, 3.29 mmol )和二环己基碳酰亚胺 ( DCC, 881 mg, 4.27 mmol )。 冰水 冷却下加入重蒸的四氢呋喃(THF, 80 mL ), 加毕自然升至室温搅拌反应, 体系中有大量白色 沉淀生成。 薄层色谱跟踪反应, 直至转化完全。 然后加入 5 g硅胶, 旋转蒸发脱溶, 干法上 柱, 用石油醚 /乙酸乙酯混合溶剂( v/v = 1: 1 )作为洗脱剂进行硅胶柱层析, 得到化合物 (5*a)-N- 羟乙基 -7'-二( 3,5-二叔丁基苯基 )膦基 -Ι,Γ-螺二氢茚 -7-甲酰胺 2 ( 660 mg, 62% ), 为白色固 体。 Mp 169-172 °C; [ ]η -122.6 (c 0.5, CH2C12); 1H NMR (400 MHz, CDC13) δ 7.41 (s, lH, Ar-H), 7.34-7.15 (m, 7H, Ar-H), 7.03 (d, J= 8.4 Hz, 2H, Ar-H), 6.71 (d, J= 7.6 Hz, 2H, Ar-H), 5.45 (t, J = 4.8 Hz, 1H, NH), 3.15-2.76 (m, 9H, OH and CH2), 2.69-2.62 (m, 1H, CH2), 2.43-2.25 (m, 3H, CH2), 1.25 (s, 18H, CH3), 1.18 (s, 18H, CH3); 31P NMR (162 MHz, CDC13) δ -16.6 (s); 13C NMR
(100 MHz, CDCI3) δ 171.4, 155.9, 155.7, 151.0, 150.2, 147.5, 146.1, 144.8, 144.7, 138.7, 138.6, 136.5, 136.3, 134.0, 133.8, 133.6, 129.0, 128.7, 127.5, 127.4, 127.3, 127.2, 126.7, 126.5, 126.0, 123.7, 121.7, 63.3, 62.4, 60.6, 43.7, 41.2, 40.8, 35.2, 35.0, 31.6, 31.5, 31.2, 31.0, 21.2, 14.4; HRMS (ESI) calcd for [M+H, C48H63N02P]+: 716.4591, Found 716.4590. 以下化合物的合成方法与实施例 1相同。
, 79%
在装有电磁搅拌的 100 mL Schlenk反应瓶中, 称入 (5*a)-N-羟乙基 -7'-二( 3,5-二叔丁基苯 基)膦基 -1,1'-螺二氢茚 -7-甲酰胺 2 ( 660 mg, 0.92 mmol )和 4-二甲基 吡啶( DMAP, 5 mg, 0.041 mmol ), 真空线上置换成氮气氛围, 加入 60 mL重蒸后脱气的二氯甲烷并搅拌均匀。 冰水浴冷却下, 依次加入 0.28 mL三乙胺和甲磺酰氯( MsCI, 105 L, 1.36 mmol ), 保温搅拌 反应 30 分钟, 再补加 1.20 mL三乙胺, 自然升至室温搅拌过夜。 薄层色谱跟踪反应, 直至 转化完全。 向体系中加入 5 g硅胶淬灭反应, 真空脱溶后直接干法上柱, 用石油醚 /乙酸乙酯 混合溶剂 (v/v = 8:l )加上 2%的三乙胺作为洗脱剂进行柱层析, 得到化合物 0¾-7- ( 4,5-二氢 噁唑 -2-基) -T-二 ( 3,5-二叔丁基苯基)膦基 -1,1'-螺二氢茚 3 ( 463 mg, 72% ), 为白色固体。 Mp 229-231 °C; [ ]2 D 2 -184.4 (c 0.5, CH2C12); JH NM (400 MHz, CDC13) δ 7.57 (d, J = 7.2 Hz, 1H, Ar-H), 7.35-7.20 (m, 5H, Ar-H), 7.06 (t, J= 7.6 Hz, 1H, Ar-H), 6.93-6.89 (m, 3H, Ar-H), 6.82 (d, J = 8.0 Hz, 2H, Ar-H), 3.75-3.69 (m, 1H, CH2), 3.56-3.50 (m, 1H, CH2), 3.41-3.28 (m, 2H,
CH2), 3.06-2.91 (m, 3H, CH2), 2.78-2.69 (m, 2H, CH2), 2.06-2.21 (m, IH, CH2), 1.99-1.89 (m, 2H, CH2), 1.20 (s, 18H, CH3), 1.17 (s, 18H, CH3); 31P NM (162 MHz, CDC13) δ -15.8 (s); 13C NM (100 MHz, CDC13) δ 165.1 , 154.0, 153.8, 150.2, 150.2, 149.9, 149.9, 149.7, 145.2, 144.7, 144.6, 138.0, 137.9, 137.5, 137.4, 133.9, 133.7, 133.0, 128.8, 128.7, 128.6, 128.4, 126.8, 126.7, 126.2, 124.5, 121.8, 121.5, 66.8, 63.5, 54.8, 40.0, 39.3, 35.1 , 35.0, 31.7, 31.3, 31.0; H MS (ESI) calcd for [M+H, C48H61NOP]+: 698.4485, Found 698.4483. 以下化合物的合成方法与实施例 2相同。
, 78%
实施例 3 : [(5*a-DTB-SIPHOX)Ir(COD)]BARF的制备
在手套箱中称取配体 (&)-7- ( 4,5-二氢噁唑 -2-基) -Ύ-二 ( 3,5-二叔丁基苯基)膦基 -Ι ,Γ- 螺二氢茚 3( 60 mg, 0.085 mmol )、 [Ir(COD)Cl]2( 32 mg, 0.047 mmol )和 NaBARF( 100 mg, 0.107 mmol )于 15 mL Schlenk反应瓶中,取出后用注射器加入新蒸的二氯甲烷( 2 mL ), 水浴 45 °C 加热搅拌反应 1小时, 取样薄层色语监测反应情况, 当配体完全络合后停止加热, 让体系自 然降至室温。 旋转蒸发脱溶后, 残余物柱层析可得到 [(5*a-DTB-SIPHOX)Ir(COD)]BARF4 ( 132 mg, 82% )0 产物为桔黄色泡沫状固体。 Mp 196。C; [ ]2 D' +122.6 (c 0.5, CH2C12); 1H NMR (300 MHz, CDCI3) δ 7.65 (brs, 9H, Ar-H), 7.50-7.35 (m, 8H, Ar-H), 7.27-7.24 (m, IH, Ar-H), 7.18-7.07 (m, 4H, Ar-H), 6.75 (brs, IH, Ar-H), 6.24 (br d, J = 10.8 Hz, IH, Ar-H), 4.38-4.24 (m, 2H, CH=CH), 3.90-3.63 (m, 3H, CH=CH and CH2), 3.39-3.29 (m, IH, CH2), 3.16-3.07 (m, IH, CH2), 2.95-2.56 (m, 4H, CH2), 2.43-2.30 (m, IH, CH2), 2.08-1.90 (m, 5H, CH2), 1.48-0.80 (m, 40H, CH2 and CH3), 0.47—0.40 (m, 3H, CH2); 31P NMR (122 MHz, CDC13) δ 16.7 (s); 13C NMR (75 MHz, CDCI3) δ 170.9, 162.8, 162.1 , 161.5, 160.8, 152.3, 150.9, 150.8, 148.0, 147.9, 147.7, 147.6,
145.5, 143.8, 134.9, 132.3, 132.2, 131.5, 130.9, 130.0, 129.7, 129.2, 128.8, 128.4, 128.0, 127.9, 127.8, 127.7, 127.6, 127.1, 126.9, 126.7, 126.4, 126.3, 124.3, 122.8, 121.1, 119.2, 117.5, 76.7, 71.9, 71.6, 70.7, 70.5, 69.4, 63.1, 51.6, 41.7, 35.0, 34.0, 31.6, 31.5, 31.0, 30.5, 30.2, 29.7, 29.6, 28.8; H MS (ESI) calcd for C56H72IrNOP+: 998.4975, Found 998.4977. 以下化合物的合成方法与实施例 3相同。
, 85%
, 82%
在手套箱中称取催化剂 [(5*a-DTB-SIPHOX)Ir(COD)]BARF4 ( 4.7 mg, 0.0025 mmol )和 2-(4- 异丁基苯基)丙烯酸 5 ( 102 mg, 0.5 mmol )于装有搅拌子的反应内管中, 密封备用。 取出后用 注射器加入三乙胺( 25 mg, 0.25 mmol )和无水甲醇(2 mL ), 将内管放置于氢化反应釜中, 在 0.6 Mpa氢气压力下, 室温搅拌反应 24小时。 而后停止搅拌, 放出氢气, 将反应体系旋蒸 浓缩后, 以 3N盐酸水溶液调节体系 pH<3 , 用乙醚( 10 mLx3 )萃取, 分液, 合并有机相, 用饱和食盐水洗涤, 无水硫酸钠干燥。 抽滤除去干燥剂, 旋蒸脱溶, 得到目标产物 6, 为白 色固体, NM 分析其转化率为 100%, 收率 96%。 Mp 53-55。C; [ ]D° -41.5 (c 2.0, ethanol); 1H NMR (400 MHz, CDC13): δ 11.27 (brs, 1H, COOH), 7.24 (d, J= 8.4 Hz, 2H, Ar-H), 7.08 (d, J = 7.6 Hz, 2H, Ar-H), 3.68 (q, J = 6.8 Hz, 1H, CH), 2.43 (d, J= 6.8 Hz, 2H, CH2), 1.88-1.78 (m, 1H, CH), 1.48 (d, J= 7.2 Hz, 3H, CH3), 0.88 (d, J= 6.4 Hz, 6H, CH3); 将其转化为甲酯后手性 GC分 析其 ee值为 90%。 对比实施例 1 :
BARF— 使用手性催化剂 L —「 1 1 」 , 在与实施例 4相同的条件下对 2-(4-异丁 基苯基)丙烯酸 5进行不对称催化氢化, 其反应结果为: 转化率为 15%, 所得产物的 ee值为 12%。 对比实施例 2:
使用手性催化剂
, 在与实施例 4相同的条件下对 2-(4-异丁 基苯基)丙烯酸 5进行不对称催化氢化, 其反应结果为: 转化率为 90% , 所得产物的 ee值为 68%。 实施例 5 : 2-苄基丙烯酸的不对称催化氢化
在手套箱中称取催化剂 [(5*a-DTB-SIPHOX)Ir(COD)]BARF4 ( 2.4 mg, 0.00125 mmol )、 2- 苄基丙烯酸 7 ( 81 mg, 0.5 mmol )和碳酸铯( 82 mg, 0.25 mmol )于装有搅拌子的反应内管中, 密封备用。 取出后用注射器加入无水甲醇(2 mL ), 将内管放置于氢化反应釜中, 在 0.6 Mpa 氢气压力下, 室温搅拌反应 12小时。 而后停止搅拌, 放出氢气, 将反应体系旋蒸浓缩后, 以 3N盐酸水溶液调节体系 pH<3 , 用乙醚(10 mLx3 )萃取, 分液, 合并有机相, 用饱和食盐 水洗涤, 无水硫酸钠干燥。 抽滤除去干燥剂, 旋蒸脱溶, 得到目标产物 8 , 为无色油状液体,
1H NMR分析其转化率为 100%, 收率 94%。 [ ]D° -31.9 (c 1.0, CH2C12); 1H NM (400 MHz, CDC13): δ 9.95 (brs, 1H, COOH), 7.31-7.18 (m, 5H, Ar-H), 3.08 (dd, J= 13.2 and 6.4 Hz, 1H, CH2) 2.77 (sextet, J = 6.8 Hz, 1H, CH), 2.67 (dd, J= 13.2 and 8.0 Hz, 1H, CH2), 1.18 (d, J= 6.8 Hz, 3H, CH3); 将其转化为苯基酰胺后手性 SFC分析其 ee值为 91%。 对比实施例 1 :
使用手性催化剂
, 在与实施例 5相同的条件下对 2-苄基丙 烯酸 7进行不对称催化氢化, 其反应结果为: 转化率为 10%, 所得产物的 ee值为 21%。 实施例 6: 2-苯乙基丙烯酸的不对称催化氢化
在手套箱中称取催化剂 [(5*a-DTB-SIPHOX)Ir(COD)]BARF4 ( 2.4 mg, 0.00125 mmol )、 2- 苯乙基丙烯酸 9 ( 88 mg, 0.5 mmol )和碳酸铯( 82 mg, 0.25 mmol ) 于装有搅拌子的反应内管 中,密封备用。取出后用注射器加入无水甲醇( 2 mL ),将内管放置于氢化反应釜中,在 0.6 Mpa 氢气压力下, 室温搅拌反应 24小时。 而后停止搅拌, 放出氢气, 将反应体系旋蒸浓缩后, 以 3N盐酸水溶液调节体系 pH<3 , 用乙醚(10 mLx3 )萃取, 分液, 合并有机相, 用饱和食盐 水洗涤, 无水硫酸钠干燥。 抽滤除去干燥剂, 旋蒸脱溶, 得到目标产物 10, 为无色油状液体, 1H NMR分析其转化率为 100%, 收率 94%。 [ ]2 D° -17.5 (c 0.9, CH2C12); 1H NM (300 MHz, CDC13): δ 10.98 (br s, 1H, COOH), 7.24-7.09 (m, 5H, Ar-H), 2.60 (t, J = 8.1 Hz, 2H, CH2), 2.50-2.38 (m, 1H, CH), 2.04-1.91 (m, 1H, CH2), 1.73-1.61 (m, 1H, CH2), 1.16 (d, J= 7.2 Hz, 3H,
CH3); 将其转化为苯基酰胺后手性 SFC分析其 ee值为 91%。 对比实施例 1 :
使用手性催化剂
, 在与实施例 6相同的条件下对 2-苯乙基 丙烯酸 9进行不对称催化氢化, 其反应结果为: 转化率为 100%, 收率 91%, 所得产物的 ee 值为 36%。 实施例 7: 2-苯氧基丙烯酸的不对称催化氢化
在手套箱中称取催化剂 [(5*a-DTB-SIPHOX)Ir(COD)]BARF4 ( 4.8 mg, 0.0025 mmol )、 2-苯 氧基丙烯酸 11 ( 32 mg, 0.20 mmol )和碳酸铯( 41 mg, 0.125 mmol )于装有搅拌子的反应内管 中,密封备用。取出后用注射器加入无水甲醇( 2 mL ),将内管放置于氢化反应釜中,在 0.6 Mpa 氢气压力下, 30 °C搅拌反应 24小时。 而后停止搅拌, 放出氢气, 将反应体系旋蒸浓缩后, 用 2N氢氧化钠水溶液转移至分液漏斗, 用石油醚萃取, 分液, 7J相以 3N盐酸水溶液调节体 系 pH<3 , 用乙醚( 10 mLx3 )萃取, 分液, 合并有机相, 用饱和食盐水洗涤, 无水硫酸钠干 燥。抽滤除去干燥剂,旋蒸脱溶,得到目标产物,为白色固体, 1H NMR分析其转化率为 100%, 收率 90%。 1H NM (400 MHz, CDC13): δ 7.70 (brs, 1H, COOH), 7.37-6.89 (m, 5H, Ar-H), 4.79 (sextet, J = 6.8 Hz, 1H, CH), 1.67 (d, J= 6.8 Hz, 3H, CH3); 将其转化为苯基酰胺后手性 SFC分 析其 ee值为 90%。
Claims
1、 一种螺环膦-噁唑啉, 其特征在于具有如下的结构式:
其中: n = 0~3 ; R2分别为 H、 ~〔8烷基、 卤代烷基、 d~C8烷氧基、 C2~C8酰氧基、 C广 C8酰基、 C2~C8酯基、 (C广 C8酰基)氨基、 二 (C广 烷基)氨基、 卤素、 苯基、 C广 烷基取 代的苯基、 羟基取代的苯基、 C广 C8烷氧基取代的苯基、 C2~C8酰氧基取代的苯基、 卤代苯基、 氨基取代的苯基、 (C广 C8酰基)氨基取代的苯基、 二 (C广 烷基)氨基取代的苯基、 C广 C8酰基 取代的苯基、 C2~C8酯基取代的苯基、 萘基、 呋喃基、 噻喻基, 或当 n≥ 2时为并脂环或并芳 环; R1和 R2可以相同, 也可以不同;
R3、 R RK R6分别为 H、 ~〔8烷基、 卤代烷基、 d~C8烷氧基、 C2~C8酰氧基、 Ci~C8 酰基、 C2~C8酯基、 (d~C8酰基)氨基、 二 ( 〜^烷基)氨基、 卤素、 苯基、 d~C8 ;¾基取代的苯 基、 羟基取代的苯基、 d~C8烷氧基取代的苯基、 C2~C8酰氧基取代的苯基、 卤代苯基、 氨基 取代的苯基、 (C广 C8酰基)氨基取代的苯基、 二 (C广 C8 ;¾基)氨基取代的苯基、 d~C8酰基取代 的苯基、 C2~C8酯基取代的苯基、 萘基、 呋喃基、 噻喻基, 或 R3~R4、 R5~R6为并脂环或芳环; R3、 R R5、 R6可以相同, 也可以不同;
R7为 d~C8 ;¾基、 苯基、 C广 C8烷基取代的苯基、 羟基取代的苯基、 磺酸基取代的苯基、 d~C8烷氧基取代的苯基、 C2~C8酰氧基取代的苯基、 卤代苯基、 氨基取代的苯基、 (C广 酰 基)- 取代的苯基、 二 (d~C8 ;¾基)氨基取代的苯基、 C广 C8酰基取代的苯基、 C2~C8酯基取 代的苯基、 萘基、 呋喃基、 噻喻基。
2、 按照权利要求 1所述的螺环膦 -噁峻啉, 其特征在于:
所述的 d~C8烷基为甲基、 乙基、 正丙基、 异丙基、 环丙基、 正丁基、 异丁基、 仲丁基、 叔丁基、 环丁基、 正戊基、 异戊基、 新戊基、 仲戊基、 叔戊基、 环戊基、 正己基、 异己基、 新 己基、 仲己基、 叔己基、 环己基、 正庚基、 异庚基、 新庚基、 仲庚基、 叔庚基、 环庚基、 正辛 基、 异辛基、 新辛基、 仲辛基、 叔辛基或环辛基;
所述的 d~C8烷氧基为甲氧基、 乙氧基、 正丙氧基、 异丙氧基、 环丙氧基、 正丁氧基、 异 丁氧基、 仲丁氧基、 叔丁氧基、 环丁氧基、 正戊氧基、 异戊氧基、 新戊氧基、 仲戊氧基、 叔戊 氧基、 环戊氧基、 正己氧基、 异己氧基、 新己氧基、 仲己氧基、 叔己氧基、 环己氧基、 正庚氧 基、 异庚氧基、 新庚氧基、 仲庚氧基、 叔庚氧基、 环庚氧基、 正辛氧基、 异辛氧基、 新辛氧基、 仲辛氧基、 叔辛氧基或环辛氧基;
所述的 d~C8酰基为甲酰基、 乙酰基、 丙酰基、 正丁酰基、 异丁酰基、 正戊酰基、 异戊酰 基、 仲戊酰基、 新戊酰基、 正己酰基、 异己酰基、 新己酰基、 仲己酰基、 正庚酰基、 异庚酰基、 新庚酰基、 仲庚酰基、 正辛酰基、 异辛酰基、 新辛酰基、 仲辛酰基、 1-环丙基甲酰基、 1-环丁 基甲酰基、 1-环戊基甲酰基、 1-环己基甲酰基、 1-环庚基甲酰基;
所述的 C2~C8酰氧基为乙酰氧基、 丙酰氧基、 正丁酰氧基、 异丁酰氧基、 正戊酰氧基、 异 戊酰氧基、 仲戊酰氧基、 新戊酰氧基、 正己酰氧基、 异己酰氧基、 新己酰氧基、 仲己酰氧基、 正庚酰氧基、 异庚酰氧基、新庚酰氧基、 仲庚酰氧基、 正辛酰氧基、 异辛酰氧基、新辛酰氧基、 仲辛酰氧基、 1-环丙基甲酰氧基、 1-环丁基甲酰氧基、 1-环戊基甲酰氧基、 1-环己基甲酰氧基、 1-环庚基甲酰氧基;
所述的 C2~C8酯基为甲氧羰基、 乙氧羰基、 丙氧羰基、 异丙氧羰基、 丁氧羰基、 异丁氧羰 基、 正戊氧羰基、 异戊氧羰基、 新戊氧羰基、 仲戊氧羰基、 叔戊氧羰基、 环戊氧羰基、 正己氧 羰基、 异己氧羰基、 新己氧羰基、 仲己氧羰基、 叔己氧羰基、 环己氧叛基、 正庚氧羰基、 异庚 氧羰基、 新庚氧羰基、 仲庚氧羰基、 叔庚氧叛基、 环庚氧羰基;
所述的卤代烷基为含氟、 氯、 溴或碘的卤代烷基。
3、 按照权利要求 1所述的螺环膦-噁唑啉, 其特征在于它包含具有相同的化学结构通式 但具有不同的立体结构和旋光性能的外消旋体、 右旋体和左旋体。
4、 按照权利要求 1所述的螺环膦 -噁峻啉, 其特征在于它是:
7- ( 4,5-二氢噁唑 -2-基 ) -7' -二(3,5-二叔丁基苯基)膦基 -1,1'-螺二氢茚
7- ( 4,5-二氢噁唑 -2-基 ) -7' -二苯基膦基- 1 , 1 '-螺二氢茚
7- ( 4,5-二氢噁唑 -2-基 ) -7' -二(4-甲基苯基)膦基 -1,1'-螺二氢茚
7- ( 4,5-二氢噁唑 -2-基 ) -7' -二(4-甲氧基苯基)膦基 -1,1'-螺二氢茚
7- ( 4,5-二氢噁唑 -2-基 ) -7' -二(3,5-二甲基苯基)膦基 -1,1'-螺二氢茚
7- ( 4,5-二氢噁唑 -2-基 ) -7' -二(3,4,5-三甲基苯基)膦基 -1,1'-螺二氢茚
7- ( 4,5-二氢噁唑 -2-基 ) -7' -二(3,5-二甲基 -4-甲氧基苯基)膦基 -1,1'-螺二氢茚
7- ( 4,5-二氢噁唑 -2-基 ) -7' -二(3,5-二叔丁基 -4-甲 苯基)膦基 -1,1'-螺二氢茚
5、 按照权利要求 1所述的螺环膦 -噁峻啉的制备方法, 其特征在于包括如下步骤: : 以取代的 7-二芳基膦基 -7'-羧基 -1,1'-螺二氢茚为起始原料, 在四氢呋喃、 二氧六环、 叔丁 基甲基醚、 乙二醇二甲醚中的一种或几种有机溶剂中, 在 1-羟基苯并三唑和 N,N-二环己基碳 酰亚胺作用下与氨基乙醇缩合反应, 得到相应的酰胺醇化合物;
所得酰胺醇化合物在 N,N-二甲基 -4-氨基吡啶的催化下, 以三乙胺或二异丙基乙基胺作为 縛酸剂, 和甲磺酰氯或对甲苯磺酰氯作用, 得到新型螺环膦 -噁唑啉, 所用溶剂为二氯甲烷、 三氯甲烷或 1,2-二氯乙烷中的一种或几种, 具体反应:
n = 0~3; R2、 R3、 R R R6、 R7的取值如权利要求 1所定义; DCC为 N,N-二环己 基碳酰亚胺; HOBt为 1-羟基苯并三唑; MsCl为甲磺酰氯; NEt3为三乙胺。
6、 一种由权利要求 1所述的螺环膦-噁唑啉制备的螺环膦-噁唑啉的铱络合物, 其特征 在于它具有如下的结构式:
7、 按照权利要求 6所述的螺环膦 -噁唑啉的铱络合物的制备方法, 其特征在于它是经过 如下步骤制备: 二氯甲烷、三氯甲烷或 1,2-二氯乙烷中的一种或几种有机溶剂中, 20~50 °C下, 螺环膦 -噁唑啉、 铱化合物和钠盐反应 , 制备得到产物, 再通过阴离子交换得到具有不同阴离
子的螺环膦 -噁唑啉的铱络合物
8、 按照权利要求 6所述的螺环膦-噁唑啉的铱络合物的应用, 其特征在于它作为催化剂 用于 α-取代丙烯酸的不对称氢化:
其中: [Ir]为权利要求 6所述的螺环膦 -噁唑啉的铱络合物; R8是卤素、 d~C8烷基、 卤代 烷基、 d~C8烷氧基、 苯甲氧基、 苯 |U&、 C2~C8酰氧基、 d~C8酰基、 C2~C8酯基、 (d~C8酰 基)氨基、 二 (d~C8烷基)氨基、 苄基、 苯乙基、 苯基、 d~C8烷基取代的苯基、 羟基取代的苯 基、 d~C8烷氧基取代的苯基、 C2~C8酰氧基取代的苯基、 卤代苯基、 氨基取代的苯基、 (Ci~C8 酰基) -氨基取代的苯基、 二 (d~C8烷基)氨基取代的苯基、 d~C8酰基取代的苯基、 C2~C8酯基 取代的苯基、 萘基、 呋喃基、 噻喻基; 星号标记的位置为手性中心。
9、 按照权利要求 8所述的的应用, 其特征在于是在氩气或氮气保护下, 将催化剂和底物 加入反应釜内管中, 加入添加剂和溶剂, 密封反应釜并用氢气置换 3 ~ 5次, 充氢气, 搅拌反 应至结束;
所述的催化氢化反应条件是: 所用溶剂是 d~C6的醇类; 催化剂用量为 0.001~1 mol%; 底 物浓度为 0.001~10.0 M; 添加剂为异丙胺、 叔丁胺、 二甲胺、 二乙胺、 二异丙胺、 二异丙基乙 基胺、 三甲胺、 三乙胺、 1,8-二氮杂双环 [5,4,0]十一 -7-烯、 1,4-二氮杂二环 [2,2,2]辛烷、 氢化钠、 氢氧化钠、 碳酸钠、 碳酸氢钠、 叔丁醇钠、 氢氧化钾、 碳酸钾、 碳酸氢钾、 叔丁醇钾、 氢氧化 铯、 碳酸铯中的一种或几种; 反应温度为 0~100 °C; 氢气压力为 0.1~10 Mpa; 反应 0.5~48小 时。
10、 按照权利要求 8所述的应用, 其特征在于所述的溶剂是甲醇; 所述的添加剂是三乙胺 或碳酸铯; 所述 α,β-不饱和羧酸是: 2-(4-异丁基苯基)丙烯酸、 2-苄基丙婦酸、 2-苯乙基丙烯酸 或 2-苯氧基丙烯酸。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011505350A JP5566372B2 (ja) | 2008-04-25 | 2009-01-20 | スピロホスフィン−オキサゾリン、その製造方法、及びその応用 |
EP09734964.1A EP2272853B1 (en) | 2008-04-25 | 2009-01-20 | Spiro phosphorus-oxazoline, synthesis and use thereof |
US12/989,610 US8450493B2 (en) | 2008-04-25 | 2009-01-20 | Spiro phosphine-oxazoline, preparation method and application thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008100528799A CN101565434B (zh) | 2008-04-25 | 2008-04-25 | 螺环膦-噁唑啉和制备方法及其应用 |
CN200810052879.9 | 2008-04-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009129700A1 true WO2009129700A1 (zh) | 2009-10-29 |
Family
ID=41216414
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2009/070229 WO2009129700A1 (zh) | 2008-04-25 | 2009-01-20 | 螺环膦-噁唑啉和制备方法及其应用 |
Country Status (5)
Country | Link |
---|---|
US (1) | US8450493B2 (zh) |
EP (1) | EP2272853B1 (zh) |
JP (1) | JP5566372B2 (zh) |
CN (1) | CN101565434B (zh) |
WO (1) | WO2009129700A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100249428A1 (en) * | 2009-03-24 | 2010-09-30 | Kurt Puentener | Process for the preparation of propionic acid derivatives |
JP2014501719A (ja) * | 2010-11-19 | 2014-01-23 | ジェジャン ジウジョウ ファーマ サイエンス アンド テクノロジー カンパニー リミテッド | キラルスピロ−ピリジルアミドフォスフィン配位子化合物、その合成方法及びその利用 |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2783448C (en) * | 2009-12-07 | 2018-11-20 | F. Hoffmann-La Roche Ag | Process for the preparation of propionic acid derivatives |
CN102391306B (zh) * | 2011-08-31 | 2014-09-03 | 浙江九洲药业股份有限公司 | 螺环苄胺-膦和制备方法及其应用 |
CN103980218B (zh) * | 2014-05-27 | 2015-12-09 | 罗梅 | 一种手性噁唑啉晶体化合物及用途 |
CN106518931B (zh) * | 2016-10-27 | 2021-08-24 | 南开大学 | 一种新型螺环膦-羧酸的铱络合物及其制备方法和应用 |
CN108794420B (zh) * | 2017-12-22 | 2021-02-12 | 浙江大学 | 基于四甲基螺二氢茚骨架的双噁唑啉配体化合物及其中间体和制备方法与用途 |
CN108659045B (zh) * | 2018-01-03 | 2020-04-10 | 浙江大学 | 基于四甲基螺二氢茚骨架的膦-噁唑啉配体化合物及其制备方法和用途 |
CN111410604B (zh) * | 2019-01-08 | 2023-06-16 | 浙江九洲药业股份有限公司 | 烯酸类化合物的不对称氢化反应 |
CN110003083B (zh) * | 2019-03-29 | 2022-08-09 | 大连万福制药有限公司 | 一种采用Ir催化剂制备S-吲哚啉-2-羧酸的工艺方法 |
CN109928995A (zh) * | 2019-04-08 | 2019-06-25 | 南开大学 | 手性螺环膦-氨基-噁唑啉三齿配体及其制备方法和应用 |
CN112209967A (zh) * | 2019-07-12 | 2021-01-12 | 瑞博(杭州)医药科技有限公司 | 一种手性螺环单膦-噁唑啉配体及其制备方法 |
CN111961080B (zh) * | 2020-08-26 | 2022-07-29 | 南方科技大学 | 氧杂螺环膦-噁唑啉配体及其制备方法和应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1884290A (zh) | 2006-07-11 | 2006-12-27 | 南开大学 | 新型螺环膦-噁唑啉配体及其在不对称催化氢化中的应用 |
-
2008
- 2008-04-25 CN CN2008100528799A patent/CN101565434B/zh active Active
-
2009
- 2009-01-20 US US12/989,610 patent/US8450493B2/en active Active
- 2009-01-20 JP JP2011505350A patent/JP5566372B2/ja active Active
- 2009-01-20 EP EP09734964.1A patent/EP2272853B1/en active Active
- 2009-01-20 WO PCT/CN2009/070229 patent/WO2009129700A1/zh active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1884290A (zh) | 2006-07-11 | 2006-12-27 | 南开大学 | 新型螺环膦-噁唑啉配体及其在不对称催化氢化中的应用 |
Non-Patent Citations (9)
Title |
---|
"Comprehensive Asymmetric Catalysis", 1999, SPRINGER-VERLAG |
HOMER, L.; SIEGEL, H.; BUTHE, H., ANGEW. CHEM.INT. ED., vol. 7, 1968, pages 942 |
J. J. CHEM. SOC., CHEM. COMMUN., 1968, pages 1445 |
LI, SHEN ET AL.: "Iridium-Catalyzed Enantioselective Hydrogenation of alpha,beta-Unsaturated Carboxylic Acids", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 130, no. 27, June 2008 (2008-06-01), pages 8584 - 8585, XP008121946 * |
OHKUMA, T.; KITAMURA, M.; NOYORI, R.: "Catalytic Asymmetric Synthesis", 2000, WILEY |
OSBORN, J. A.; JARDINE, F. H.; YOUNG, J. F.; WILKINSON, G. J., CHEM. SOC. A, 1966, pages 1711 |
See also references of EP2272853A4 |
ZHANG, ZHANHUI ET AL.: "Synthesis and Application ofChiral Priro Ligands in Asymmertric Catalysis", CHINESE JOURNAL OF ORGANIC CHEMISTRY, vol. 25, no. 4, 2005, pages 355 - 363, XP008143635 * |
ZHU, SHOUFEI ET AL.: "Well-Defined Chiral Spiro Iridium/Phosphine-Oxazoline Cationic Complexes for Highly Enantioselective Hydrogenation of Imines at Ambient Pressure", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 128, no. 39, 2006, pages 12886 - 12891, XP002631106 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100249428A1 (en) * | 2009-03-24 | 2010-09-30 | Kurt Puentener | Process for the preparation of propionic acid derivatives |
US8450496B2 (en) * | 2009-03-24 | 2013-05-28 | Hoffman-La Roche Inc. | Process for the preparation of propionic acid derivatives |
JP2014501719A (ja) * | 2010-11-19 | 2014-01-23 | ジェジャン ジウジョウ ファーマ サイエンス アンド テクノロジー カンパニー リミテッド | キラルスピロ−ピリジルアミドフォスフィン配位子化合物、その合成方法及びその利用 |
US8962839B2 (en) | 2010-11-19 | 2015-02-24 | Zhejiang Jiuzhou Pharma Science & Technology Co., Ltd. | Chiral spiro-pyridylamidophosphine ligand compound, synthesis method therefor and application thereof |
Also Published As
Publication number | Publication date |
---|---|
US20110118472A1 (en) | 2011-05-19 |
US8450493B2 (en) | 2013-05-28 |
EP2272853A4 (en) | 2011-05-18 |
EP2272853B1 (en) | 2014-08-27 |
JP5566372B2 (ja) | 2014-08-06 |
JP2011518788A (ja) | 2011-06-30 |
EP2272853A1 (en) | 2011-01-12 |
CN101565434A (zh) | 2009-10-28 |
CN101565434B (zh) | 2012-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009129700A1 (zh) | 螺环膦-噁唑啉和制备方法及其应用 | |
WO2009129701A1 (zh) | 铱络合物在不饱和羧酸不对称催化氢化中的应用 | |
TWI803692B (zh) | 用於製備6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯啶-3-基]氧基苯基]-8,9-二氫-7h-苯并[7]輪烯-2-甲酸甲酯之方法 | |
CN108546238B (zh) | α-酮酰胺类化合物的不对称氢化方法 | |
US8557980B2 (en) | Methods for forming protected organoboronic acids | |
JPH07503734A (ja) | 鏡像体選択的オキサアザボロリジン | |
WO2013029446A1 (zh) | 螺环苄胺-膦和制备方法及其应用 | |
CN111039767B (zh) | 一种三唑卡宾催化制备氘代醛的方法 | |
JP2000136193A (ja) | 光学活性ビスホスフィノメタン並びにそれらのロジウム又は銅錯体を用いる不斉合成 | |
CN107880022B (zh) | 一种手性含咪唑吡啶酰胺类的化合物及其制备方法和应用 | |
JPWO2022014414A5 (zh) | ||
CN112724171A (zh) | 一种2-膦酰基-3-氟代乙烯基吲哚化合物及其制备方法 | |
EP1601635A1 (en) | Process for producing optically active alcohol in the presence of rhodium, a chiral ferrocenyldiphosphine and an optically active diamine | |
CN112745350B (zh) | 一种4-膦酸烷基酯取代吲哚化合物的合成方法 | |
JPS63503543A (ja) | カルボニル化合物の不斉水素化方法 | |
JPH04502165A (ja) | キラルなスルタム | |
WO2008044702A1 (fr) | Procédé de production d'un dérivé azabicycloalcanol | |
JP4780542B2 (ja) | 3−アミノピロリジン誘導体の製造方法 | |
CN117946180A (zh) | 一种手性铱配合物及其制备方法和应用 | |
CN110357923A (zh) | 二氨基二膦四齿配体、其钌络合物及上述两者的制备方法和应用 | |
Leung et al. | Synthesis of dihydrobenzazaphosphole ligands via an intramolecular cyclisation reaction | |
Vela | The synthesis of constrained and benzannulated derivatives of the essential amino acids tyrosine and tryptophan | |
JPH03188091A (ja) | 光学活性3,4―ビスホスフィノピロリジン化合物 | |
JP2011500646A (ja) | 有機金属錯体に対応するキラル三座化合物、その調製方法、および不斉触媒反応における配位子としての前記化合物ならびに錯体の使用 | |
JPH0971592A (ja) | 光学活性モノホスフィノカルボン酸誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09734964 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011505350 Country of ref document: JP Ref document number: 12989610 Country of ref document: US Ref document number: 2009734964 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |